Atsena Therapeutics is a clinical-stage gene therapy company developing best-in-class treatments for the reversal or prevention of blindness from inherited retinal diseases. The company’s lead program is evaluating ATSN-201 in an ongoing Phase 1 / 2 / 3 clinical trial for X-linked retinoschisis (XLRS), a genetic condition that is typically diagnosed in childhood and leads to blindness later in life. ATSN-101, Atsena’s first-in-class, investigational gene therapy for Leber congenital amaurosis type 1 (LCA1), has completed a Phase 1 / 2 trial with positive results (https://doi.org/10.1016/s0140-6736(24)01447-8). Atsena is advancing ATSN-101 toward the initiation of a global pivotal trial as part of its exclusive strategic collaboration with Nippon Shinyaku Co., Ltd. Atsena’s pipeline is powered by novel adeno-associated virus (AAV) technology tailored to overcome the hurdles presented by inherited retinal diseases. Founded by pioneers in ocular gene therapy, Atsena is led by an experienced team dedicated to addressing the needs of patients with vision loss.
Company Details
- Employees
- 31
- Address
- Administrator Jobs
- Industry
- Biotechnology
- Website
- https://atsenatx.com/
- Keywords
- https://lnkd.in/e8ztHj9.
Atsena Therapeutics Questions
Atsena Therapeutics's website is https://atsenatx.com/
Atsena Therapeutics's LinkedIn profile is https://www.linkedin.com/company/atsenatx
Atsena Therapeutics has
31 employees.
View email and phone details for 31
employees at Atsena Therapeutics.
Atsena Therapeutics's industry is
Biotechnology
Atsena Therapeutics's top competitors are
Nanoscope Therapeutics Inc.,
Ocugen,
Beacon Therapeutics,
Neurona Therapeutics,
Recode Therapeutics,
4d Molecular Therapeutics,
Kriya Therapeutics, Inc.,
Bridgebio,
Beam Therapeutics,
Opus Genetics.
Atsena Therapeutics's categories are Biotechnology
